SCHEMBL3018635

SCHEMBL3018635

Cc1ccc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4ccc(F)cc4F)CC3)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
PKM P14618 2/20 0.42
GBA1 P04062 1/20 0.42
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.40
RAB9A P51151 3/20 0.39
GAA P10253 1/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM2B Q8NHM5 1/20 0.38
PKLR P30613 1/20 0.38
POLB P06746 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007521 0.93 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2L3MBTL1LMNA
SCHEMBL3007657 0.92 SMN1; SMN2 (0.41) ALDH1A1MAPTSMN1; SMN2L3MBTL1GBA1
SCHEMBL3002474 0.90 GBA1 (0.46) ALDH1A1MAPTSMN1; SMN2L3MBTL1PKM
SCHEMBL3002719 0.88 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2L3MBTL1PKM
SCHEMBL3014133 0.88 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2L3MBTL1PKM
SCHEMBL3016763 0.87 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2L3MBTL1PKM
SCHEMBL3013261 0.86 ALDH1A1 (0.47) ALDH1A1MAPTSMN1; SMN2L3MBTL1PKM
SCHEMBL3014062 0.86 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2L3MBTL1PKM
SCHEMBL3009371 0.86 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2L3MBTL1PKM
SCHEMBL3014613 0.86 GPR6 (0.38) SMN1; SMN2LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPT 18/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.